On August 15, 2024, Director William Rastetter sold 14,250 shares of Neurocrine Biosciences Inc, owning 37,491 shares now. The company focuses on treatments for neurological and endocrine-related diseases. Insider trends show a preference for selling.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing